Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05987527 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Enrolling by Invitation to Active, Not Recruitingv6
  2. Enrollment target: 21 to 11v5 Show 4 more changesShow less
    • Primary and study completion dates: Sep 4, 2039 to Jun 11, 2039
    • Interventions: Blood sample (Diagnostic Test), Lifestyle questionnaire (Other), Urine sample (Diagnostic Test) to Blood sample (Diagnostic Test)
    • Secondary endpoints: 10 to 8
    • Study description shortened, about 32 words
  3. Study sites: 6 to 5v4
  4. Secondary endpoints revised (10)v3
  5. Primary endpoints revised (2)
    • Secondary endpoints revised (10)
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This long-term follow-up study is being conducted to collect long-term (up to 15 years post-infusion) safety and tolerability data from subjects enrolled in studies evaluating TX200-TR101.
Trial Details
NCT Number NCT05987527
Lead Sponsor Sangamo Therapeutics
Conditions
(from sponsor)		 Kidney Transplant Rejection, End Stage Renal Disease
Related terms Kidney Failure, Chronic
Enrollment 11 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov